INSP
Inspire Medical Systems, Inc.
Next earnings Aug 3, 2026 (after close) · consensus $-0.07 EPS, $202M rev
Last earnings -3.3% on 2026-05-04
$45.72
▲ +5.22%$45.72▼ -64.83%
over 1Y
L $40.05EODHDH $143.99
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+5.2%
1W+10.6%
1M+8.3%
3M-8.8%
YTD-50.4%
1Y-64.8%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 24 analysts
Hold
Revenue grew 13.6% YoY.
Revenue (FY2025) $912M · FY2025
The read
Middling fundamentals offset by an attractive price (~306% below fair value) — worth a look on the value angle.
Inspire Medical Systems, Inc. shows $912M in FY2025 revenue (+13.6% YoY), a 15.9% net margin, and 18.6% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $233M | $408M | $625M | $803M | $912M |
| Gross profit | $200M | $342M | $528M | $680M | $779M |
| Operating income | -$39.9M | -$47.6M | -$40.3M | $36.1M | $51.0M |
| Net income | -$42.0M | -$44.9M | -$21.2M | $53.5M | $145M |
| Diluted EPS | -$1.54 | -$1.60 | -$0.72 | $1.75 | $4.89 |
| Net margin | -18.0% | -11.0% | -3.4% | 6.7% | 15.9% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$1.23B
EV / EBITDA18.9
EV / Sales1.3
EV / FCF15.6
P / FCF16.7
PEG (trailing)0.05
Earnings yield11.1%
FCF yield6.0%
Quality & risk
ROIC (est.)5.0%
Free cash flow$78.5M
Total debt$24.5M
Net cash$80.3M
Altman Z-Score7.83 safe
Piotroski F-Score7/9
Capital returns
Buyback yield13.4%
Dividend yield (est.)—
Shareholder yield13.4%
Shares Δ YoY-3.6%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-262026-06-26open ↗SDFiling2026-06-01open ↗SCHEDULE 13GFiling2026-05-27open ↗4Period ending 2026-05-152026-05-19open ↗144Filing2026-05-15open ↗4Period ending 2026-05-142026-05-15open ↗SCHEDULE 13G/AFiling2026-05-15open ↗SCHEDULE 13G/AFiling2026-05-14open ↗144Filing2026-05-14open ↗4Period ending 2026-05-082026-05-11open ↗144Filing2026-05-08open ↗S-8Filing2026-05-07open ↗
Frequently asked
- Is Inspire Medical Systems, Inc. (INSP) a buy?
- INSP currently carries a Hold rating with 3/5 conviction, derived from its latest SEC filings. Revenue grew 13.6% YoY.
- What is INSP's fair value?
- A Modified-Graham model based on INSP's SEC fundamentals estimates a fair value of about $185.82. It is an estimate from reported earnings, not a price target.
- Is INSP overvalued or undervalued?
- Against a Modified-Graham fair-value estimate, INSP currently appears undervalued relative to its SEC-grounded earnings power.
- What is Inspire Medical Systems, Inc.'s quality score?
- INSP scores 83.27450980392156/100 (grade A) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001609550, latest 10-Q filed 2026-05-04) · EODHD · as of 6/26/2026, 6:18:05 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.